Progress in Neurobiology· 2026Q1
ABCA7 deficiency exacerbates glutamate excitotoxicity in Alzheimer’s disease mice – A new pharmacological target for Glu-related neurotoxicity
- 3citations
- Q1SCImago
- 2026year
Short summary
ABCA7 deficiency amplifies glutamate-induced neurotoxicity in Alzheimer's disease (AD) mouse models, linked to altered neurotransmitter metabolism and transport, suggesting ABCA7 as a novel therapeutic target for AD-related neurodegeneration.
AI-generated from the title and abstract; the full text is not read.
Key points
- ABCA7 deficiency exacerbates glutamate-induced neurotoxicity in Alzheimer's disease (AD) mouse models.
- Amyloid-beta deposition is identified as a trigger for increased glutamatergic transmission in these models.
- ABCA7 ablation leads to diminished neurotransmitter degradation and increased expression of NMDA, AMPA, and GABA A receptors/transporters.
- The study provides the first comprehensive explanation of ABCA7's role in amplifying neurotoxic effects via lipid interactions and modulation of Glu-GABA systems.
AI-generated from the title and abstract; the full text is not read.
Abstract
Increasing attention has been directed towards the perturbation of glutamate (Glu) and γ-aminobutyric acid (GABA) homeostasis during the pathogenesis of Alzheimer's disease (AD). The prevailing disequilibrium, stemming from hyperactivation of the glutamatergic system, culminates in progressive neuronal impairment and cognitive deterioration. This study aimed to elucidate the contributory role of the ATP-binding cassette transporter A7 (ABCA7), identified as the second most critical genetic determinant in AD, in glutamatergic-associated neurotoxicity. This endeavor sought to advance molecular comprehension of neurological disorders where Glu-GABA neurotransmission represents a pivotal pharmacotherapeutic target. Utilizing multi-omics approaches, we rigorously analyzed four distinct mouse models, both with and without APPtg and ABCA7 expression, to simulate varied pathological and ABCA7-deficient states. Our results revealed amyloid-beta (Aβ) deposition as a catalyst for surging glutamatergic transmission. Notably, ABCA7 ablation exacerbated glutamatergic-induced neurotoxicity, attributed to diminished enzymatic activity related to neurotransmitter degradation and amplified expression levels of specific neurotransmitter transport proteins and receptor subunits, notably NMDA, AMPA, and GABA A . These findings furnish the first comprehensive description elucidating ABCA7's amplification of neurotoxic effects through modulation of Glu-GABA neurotransmission systems in neurodegenerative contexts, primarily mediated by lipid interaction. The evidence underscores ABCA7's imperative role in shaping future pharmacological strategies aimed at counteracting neurodegeneration precipitated by Glu-mediated neurotoxicity. This research advances the frontier for therapeutic exploration to ameliorate the deleterious neural consequences characteristic of neurodegenerative pathologies.
The authors' abstract, as published at the source. Progress in Neurobiology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Cellular and Molecular Neuroscience
Cellular and Molecular NeuroscienceNeuroscience